Antagonism to estradiol in the mouse: Reduced entry of receptors complexed with 4-hydroxytamoxifen into a Mg2+-soluble chromatin fraction

Edward J. Pavlik, John R. van Nagell, Katherine Nelson, Holly Gallion, Elvis S. Donaldson, Daniel E. Kenady, Janina Baranowska-Kortylewicz

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Antagonism to estradiol has been examined in murine uteri. When tampxifen was administered simultaneously with estradiol (0.05 μg/mouse), it was able to act as an antagonist over the dosage range 0.05-50 μg/mouse. The metabolite 4-hydroxytamoxifen (4OH-tamoxifen) had high affinity for estrogen receptors and was a slightly better antagonist over the dosage range 0.005–1 μg/mouse. After uteri were exposed to either [3H]estradiol or [3H]4OH-tamoxifen, receptors complexed with [3H]estradiol penetrated a chromatin region, which was released as the Mg2+-soluble chromatin fraction after DNAase I treatment more readily than receptors complexed with [3H]4OH-tamoxifen. [3H]4OH-tamoxifen-receptor complexes could not be driven into the Mg2+-soluble chromatin fraction by increasing the ligahd concentration during translocation. Relative to [3H]estradiol, significantly more [3H]4OH-tamoxifen was observed to associate with uterine cells and to penetrate the nucleus so that neither restricted entry nor extranuclear partitioning could explain the failure of [3H]4OH-tamoxifen-receptor complexes to enter the Mg2+-soluble chromatin. Bleomycin, an agent that interrupts DNA continuity, did not interfere with the appearance of estrogen receptor activity in the Mg2+-soluble chromatin fraction. Preincubation of intact uteri in the presence of molybdate (20 mM) did inhibit the appearance of receptor activity in this chromatin fraction; however, this effect did not occur through inhibition of receptor activation, but, rather, through the lowering of receptor activity in all chromatin fractions. In the studies reported here, the chromatin positioning of estrogen receptors complexed with estradiol appeared to be distinct from the positioning of receptors complexed with 4OH-tamoxiferi. These observations suggest an additional basis from which the mechanisms separating the actions of estrogen agonists and antagonists can be approached.

Original languageEnglish (US)
Pages (from-to)1924-1934
Number of pages11
JournalEndocrinology
Volume118
Issue number5
DOIs
StatePublished - Jan 1 1986

Fingerprint

Chromatin
Estradiol
Estrogen Receptors
Uterus
Estrogen Antagonists
afimoxifene
Deoxyribonuclease I
Bleomycin
DNA

ASJC Scopus subject areas

  • Endocrinology

Cite this

Antagonism to estradiol in the mouse : Reduced entry of receptors complexed with 4-hydroxytamoxifen into a Mg2+-soluble chromatin fraction. / Pavlik, Edward J.; van Nagell, John R.; Nelson, Katherine; Gallion, Holly; Donaldson, Elvis S.; Kenady, Daniel E.; Baranowska-Kortylewicz, Janina.

In: Endocrinology, Vol. 118, No. 5, 01.01.1986, p. 1924-1934.

Research output: Contribution to journalArticle

Pavlik, Edward J. ; van Nagell, John R. ; Nelson, Katherine ; Gallion, Holly ; Donaldson, Elvis S. ; Kenady, Daniel E. ; Baranowska-Kortylewicz, Janina. / Antagonism to estradiol in the mouse : Reduced entry of receptors complexed with 4-hydroxytamoxifen into a Mg2+-soluble chromatin fraction. In: Endocrinology. 1986 ; Vol. 118, No. 5. pp. 1924-1934.
@article{0d366cd95f4f4bcd9ec1b438f2d73691,
title = "Antagonism to estradiol in the mouse: Reduced entry of receptors complexed with 4-hydroxytamoxifen into a Mg2+-soluble chromatin fraction",
abstract = "Antagonism to estradiol has been examined in murine uteri. When tampxifen was administered simultaneously with estradiol (0.05 μg/mouse), it was able to act as an antagonist over the dosage range 0.05-50 μg/mouse. The metabolite 4-hydroxytamoxifen (4OH-tamoxifen) had high affinity for estrogen receptors and was a slightly better antagonist over the dosage range 0.005–1 μg/mouse. After uteri were exposed to either [3H]estradiol or [3H]4OH-tamoxifen, receptors complexed with [3H]estradiol penetrated a chromatin region, which was released as the Mg2+-soluble chromatin fraction after DNAase I treatment more readily than receptors complexed with [3H]4OH-tamoxifen. [3H]4OH-tamoxifen-receptor complexes could not be driven into the Mg2+-soluble chromatin fraction by increasing the ligahd concentration during translocation. Relative to [3H]estradiol, significantly more [3H]4OH-tamoxifen was observed to associate with uterine cells and to penetrate the nucleus so that neither restricted entry nor extranuclear partitioning could explain the failure of [3H]4OH-tamoxifen-receptor complexes to enter the Mg2+-soluble chromatin. Bleomycin, an agent that interrupts DNA continuity, did not interfere with the appearance of estrogen receptor activity in the Mg2+-soluble chromatin fraction. Preincubation of intact uteri in the presence of molybdate (20 mM) did inhibit the appearance of receptor activity in this chromatin fraction; however, this effect did not occur through inhibition of receptor activation, but, rather, through the lowering of receptor activity in all chromatin fractions. In the studies reported here, the chromatin positioning of estrogen receptors complexed with estradiol appeared to be distinct from the positioning of receptors complexed with 4OH-tamoxiferi. These observations suggest an additional basis from which the mechanisms separating the actions of estrogen agonists and antagonists can be approached.",
author = "Pavlik, {Edward J.} and {van Nagell}, {John R.} and Katherine Nelson and Holly Gallion and Donaldson, {Elvis S.} and Kenady, {Daniel E.} and Janina Baranowska-Kortylewicz",
year = "1986",
month = "1",
day = "1",
doi = "10.1210/endo-118-5-1924",
language = "English (US)",
volume = "118",
pages = "1924--1934",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "The Endocrine Society",
number = "5",

}

TY - JOUR

T1 - Antagonism to estradiol in the mouse

T2 - Reduced entry of receptors complexed with 4-hydroxytamoxifen into a Mg2+-soluble chromatin fraction

AU - Pavlik, Edward J.

AU - van Nagell, John R.

AU - Nelson, Katherine

AU - Gallion, Holly

AU - Donaldson, Elvis S.

AU - Kenady, Daniel E.

AU - Baranowska-Kortylewicz, Janina

PY - 1986/1/1

Y1 - 1986/1/1

N2 - Antagonism to estradiol has been examined in murine uteri. When tampxifen was administered simultaneously with estradiol (0.05 μg/mouse), it was able to act as an antagonist over the dosage range 0.05-50 μg/mouse. The metabolite 4-hydroxytamoxifen (4OH-tamoxifen) had high affinity for estrogen receptors and was a slightly better antagonist over the dosage range 0.005–1 μg/mouse. After uteri were exposed to either [3H]estradiol or [3H]4OH-tamoxifen, receptors complexed with [3H]estradiol penetrated a chromatin region, which was released as the Mg2+-soluble chromatin fraction after DNAase I treatment more readily than receptors complexed with [3H]4OH-tamoxifen. [3H]4OH-tamoxifen-receptor complexes could not be driven into the Mg2+-soluble chromatin fraction by increasing the ligahd concentration during translocation. Relative to [3H]estradiol, significantly more [3H]4OH-tamoxifen was observed to associate with uterine cells and to penetrate the nucleus so that neither restricted entry nor extranuclear partitioning could explain the failure of [3H]4OH-tamoxifen-receptor complexes to enter the Mg2+-soluble chromatin. Bleomycin, an agent that interrupts DNA continuity, did not interfere with the appearance of estrogen receptor activity in the Mg2+-soluble chromatin fraction. Preincubation of intact uteri in the presence of molybdate (20 mM) did inhibit the appearance of receptor activity in this chromatin fraction; however, this effect did not occur through inhibition of receptor activation, but, rather, through the lowering of receptor activity in all chromatin fractions. In the studies reported here, the chromatin positioning of estrogen receptors complexed with estradiol appeared to be distinct from the positioning of receptors complexed with 4OH-tamoxiferi. These observations suggest an additional basis from which the mechanisms separating the actions of estrogen agonists and antagonists can be approached.

AB - Antagonism to estradiol has been examined in murine uteri. When tampxifen was administered simultaneously with estradiol (0.05 μg/mouse), it was able to act as an antagonist over the dosage range 0.05-50 μg/mouse. The metabolite 4-hydroxytamoxifen (4OH-tamoxifen) had high affinity for estrogen receptors and was a slightly better antagonist over the dosage range 0.005–1 μg/mouse. After uteri were exposed to either [3H]estradiol or [3H]4OH-tamoxifen, receptors complexed with [3H]estradiol penetrated a chromatin region, which was released as the Mg2+-soluble chromatin fraction after DNAase I treatment more readily than receptors complexed with [3H]4OH-tamoxifen. [3H]4OH-tamoxifen-receptor complexes could not be driven into the Mg2+-soluble chromatin fraction by increasing the ligahd concentration during translocation. Relative to [3H]estradiol, significantly more [3H]4OH-tamoxifen was observed to associate with uterine cells and to penetrate the nucleus so that neither restricted entry nor extranuclear partitioning could explain the failure of [3H]4OH-tamoxifen-receptor complexes to enter the Mg2+-soluble chromatin. Bleomycin, an agent that interrupts DNA continuity, did not interfere with the appearance of estrogen receptor activity in the Mg2+-soluble chromatin fraction. Preincubation of intact uteri in the presence of molybdate (20 mM) did inhibit the appearance of receptor activity in this chromatin fraction; however, this effect did not occur through inhibition of receptor activation, but, rather, through the lowering of receptor activity in all chromatin fractions. In the studies reported here, the chromatin positioning of estrogen receptors complexed with estradiol appeared to be distinct from the positioning of receptors complexed with 4OH-tamoxiferi. These observations suggest an additional basis from which the mechanisms separating the actions of estrogen agonists and antagonists can be approached.

UR - http://www.scopus.com/inward/record.url?scp=0022646940&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022646940&partnerID=8YFLogxK

U2 - 10.1210/endo-118-5-1924

DO - 10.1210/endo-118-5-1924

M3 - Article

C2 - 2422013

AN - SCOPUS:0022646940

VL - 118

SP - 1924

EP - 1934

JO - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 5

ER -